Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study

Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study

We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia development. PCR-confirmed SARS-CoV-2-infected patients without pneumonia were enrolled (2:1) within 10 days of symptomat...

Full description

Bibliographic Details
Main Authors: Rujipas Sirijatuphat, Weerawat Manosuthi, Suvimol Niyomnaitham, Andrew Owen, Katherine Kradangna Copeland, Lantharita Charoenpong, Manoch Rattanasompattikul, Surakameth Mahasirimongkol, Nuanjun Wichukchinda, Kulkanya Chokephaibulkit
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Emerging Microbes and Infections
Subjects:
COVID-19
Favipiravir
Thailand
antiviral
RdRp inhibitor
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2022.2117092

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2022.2117092

Similar Items